The platelet inhibitory effects of the Phase 3 anticancer agent and nitric oxide (NO) donor, RRx-001, (1-bromoacetyl-3,3-dinitroazetidine) were examined ex vivo and compared with the diazeniumdiolate NO donor, diethylenetriamine NONOate (DETA-NONOate), which spontaneously releases nitric oxide in aqueous solution. In the absence of red blood cells and in a dose-dependent manner, DETA-NONOate strongly inhibited platelet aggregation induced by several stimuli (ADP, epinephrine and collagen) whereas RRx-001 only slightly inhibited platelet aggregation under the same conditions in a dose-dependent manner; these antiaggregant effects were blocked when both DETANONOate and RRx-001 were co-incubated with carboxy-PTIO (CPTIO 0.01-100 micromol), a widely accepted NO scavenger. However, in the presence of red blood cells from healthy human donors, RRx-001, which binds covalently to haemoglobin (Hb) and catalyses the production of NO from endogenous nitrite, more strongly inhibited the aggregation of platelets than DETA-NONOate in a dose-dependent manner likely because haemoglobin avidly scavenges nitric oxide and reduces its half-life; the RRx-001- , which makes RRx-001 a more physiologically relevant inhibitor of platelet aggregation than other nitric oxide donors, whose effects are attenuated in the presence of red blood cells. Therefore, RRx-001-mediated platelet inhibition is a potentially useful therapeutic property, especially in hypercoagulable cancer patients that are at an increased risk of thrombotic complications.
| INTRODUCTION
It is well known that haemoglobin (Hb) in circulating red blood cells (RBCs) acts as a high-affinity depot or storage pool for nitric oxide (NO) 1 and that, cell-free Hb, an even more avid scavenger of NO, contributes to the pathology of haemolytic anaemias like sickle cell disease, malaria and transfusion of older stored blood. 2 Less well known is that nitrite enzymatically reacts with deoxyhaemoglobin to generate nitric oxide in the RBC, which serves as an "erythrocrine,"
that is endocrine carrier and exporter of NO . in the circulation under low oxygen conditions. stimuli such as collagen, 4 adenosine diphosphate (ADP), epinephrine, thromboxane A2 (TxA2) and thrombin. In addition to sealing vascular breaches, platelets are also implicated in the pathogenesis of hypertension, hypercholesterolaemia, cigarette smoking, 5 diabetes and cancer 6 and their activation predisposes to thrombotic vascular complications, leading to ischaemia and the development of coronary, cerebrovascular and peripheral artery disease. 7 Excessive activation, therefore, is tightly regulated, mostly through the action of inhibitory factors such as NO, released continually by eNOS (endothelial nitric oxide synthase) in the endothelium (except under hypoxic conditions when its activity is impaired), that limits both platelet adhesion to the vascular wall and platelet aggregation by activation of cGMP/ PKG pathway, which in turn leads to reduction in concentration of Ca 2+ with vasodilation and increased blood flow. 8, 9 Nonetheless, a common feature of endothelium dysfunction is reduced NO bioavailability, which induces abnormal platelet activation leading to thrombus formation and vessel occlusion. 
| RBC aggregation
Red blood cells were separated from the blood by centrifugation at 
| Coagulation studies
Coagulation studies were performed on plasma separated at 4°C from citrated whole blood. 
| Platelet aggregation and ATP release
Whole blood was centrifuged at 1100 g for 10 minutes. 
| Nitrite/nitrate levels in samples
Plasma proteins were removed by adding an equivolume of methanol and centrifuged at 5: 15000 RPM (0.025 Gs) at 4°C.
Concentrations of nitrite and nitrate in the supernatant were measured with a NOx analyser (ENO-20; Eicom, Kyoto, Japan). This analyser combines the Griess method and high-performance liquid chromatography.
| Statistical analysis
All data are means ± SD. Statistical analysis was analysed by GraphPad Prism version 6 (GraphPad software Inc., San Diego, CA, USA). 
| RRx-001 had no effect on RBC rouleaux formation or aggregation
In red blood cells exposed to RRx-001, no rouleaux formation or 
| The platelet inhibitory effects of RRx-001 and

DETA-NONOate are reversed by the addition of CPTIO, a nitric oxide scavenger
Platelet aggregation was studied in platelet-rich plasma (PRP). In PRP, DETA-NONOate and RRx-001 both exhibited a dose-dependent inhibition of platelet aggregation induced by 8 μmol/L ADP; however, the effect of DETA-NONOate on platelet aggregation was much more pronounced that RRx-001. However, the antiplatelet effects of both DETA-NONOate and RRx-001 were reversed by CPTIO, an NO scavenger, which suggests an NO-mediated action. (Figure 4 ). 
| The platelet inhibitory effects of
| The addition of nitrite enhanced the inhibitory action of RRx-001 on platelet activation
The potential effect of nitrite addition (0.1-10 μmol/L) on the RRx-001-mediated regulation of platelet activity, given that RRx-001- | 5081
between RRx-001 and the CVA event in this one patient is improbable (although not impossible).
Currently, RRx-001 is dosed as a single agent and in combination with standard chemotherapy and radiation; its mechanism of anticancer action is thought to be related to pan-epigenetic inhibition 21, 22 and the repolarization of tumour associated macrophages and neutrophils 23 ; however, the synergistic activity between nitrite and RRx-001 on platelet aggregation suggests that co-administration with nitrite, which would lead to overproduction of NO . and other genotoxic reactive nitrogen species under the hypoxic conditions presumably endemic only to tumours, may not only result in enhanced cytotoxicity but also improved safety, as patients with cancer are prone to increased platelet activation and thromboembolic events.
In conclusion, these data, which confirm previous observations that RRx-001 catalyses the conversion of nitrite to nitric oxide from deoxyhaemoglobin 24 suggest that RRx-001, apart from its anticancer effects and unlike all other known NO-donating agents, reduces platelet aggregation and protects against thromboembolism as haemoglobin and haematocrit levels increase. Moreover, also unlike other known NO-donating agents, because RRx-001 mediates increased nitric oxide production under hypoxic conditions, NO is released locally on demand where it is most needed when eNOS is impaired.
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